Screener
Icahn Enterprises IEP Pharma — Total Assets
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| Property, plant and equipment, net | — | 2,282 | 366 | 148 | 765 | 52 | — | 3 | 3,616 |
| Goodwill and intangible assets, net | — | 130 | 312 | 20 | — | 20 | 137 | — | 619 |
| Other assets | 1,132 | 378 | 388 | 80 | 109 | 22 | 9 | 245 | 2,363 |
| Total assets | $4,323 | $4,469 | $1,290 | $428 | $1,157 | $211 | $216 | $796 | $12,890 |
| LIABILITIES AND EQUITY | |||||||||
| Accounts payable, accrued expenses and other liabilities | $752 | $1,578 | $711 | $110 | $28 | $38 | $63 | $75 | $3,355 |
| Securities sold, not yet purchased, at fair value | 1,000 | — | — | — | — | — | — | — | 1,000 |
| Debt | — | 1,783 | 25 | 129 | 1 | 25 | — | 4,426 | 6,389 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — total assets?
- Icahn Enterprises (IEP) reported pharma — total assets of $216M in Q2 2026.
- How has Icahn Enterprises's pharma — total assets changed year-over-year?
- Icahn Enterprises's pharma — total assets decreased by 14.6% year-over-year, from $253M to $216M.
- What is the long-term trend for Icahn Enterprises's pharma — total assets?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — total assets has grown at a -5.4% compound annual growth rate (CAGR), from $1.26B to $1.01B.
- What does pharma — total assets mean?
- The total value of all resources owned or controlled by the pharmaceutical segment, including tangible and intangible assets. This metric provides a comprehensive view of the capital base deployed to support drug development and commercial operations. It serves as a primary indicator of the segment's scale and resource intensity.
Ask your AI about Icahn Enterprises's pharma — total assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude